- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01075113
Sorafenib and Vorinostat in Treating Patients With Advanced Liver Cancer
A Phase I Study of Sorafenib and Vorinostat in Advanced Hepatocellular Carcinoma
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Outline: This is a dose-escalation study of vorinostat. The purpose of this research study is to test the safety and effectiveness of a combination of two cancer drugs, sorafenib (Nexavar) and vorinostat (Zolinza), in advanced liver cancer (hepatocellular carcinoma). Advanced means that the cancer has spread too far to consider surgery. Approximately 19 people will take part in this study.
After enrollment of 6 patients at sorafenib 400 mg orally twice a day and vorinostat 300 mg orally, only 2 of the 6 patients were evaluable for DLT (no DLTs). The other 4 patients were not evaluable for DLT because of required dose modifications. Because of this dose modification need, Cohort A has been modified to include 2 dose levels: Dose level A-1a (sorafenib 400 mg orally twice a day and vorinostat 200 mg orally once a day) and dose level A1 (sorafenib 400 mg orally twice a day with vorinostat 100 mg orally once a day). The starting dose upon reopening after approval of this version will be dose level A-1a. Dose level A1 will only be used if dose level A-1a is not tolerable.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Virginia
-
Richmond, Virginia, United States, 23298
- Virginia Commonwealth University/Massey Cancer Center
-
Richmond, Virginia, United States, 23249
- Hunter Holmes McGuire VA Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Diagnosis of HCC by biopsy-proven pathologic diagnosis or by clinical criteria as defined below:
* Clinical criteria to be met if patient has a history of cirrhosis or chronic hepatitis B infection:
- Imaging abnormalities > 1 cm in size with classic enhancement by magnetic resonance imaging (MRI) or triple-phase computed tomography (CT) scan
- Alpha-fetoprotein (AFP) of any value
- Performance status Eastern Cooperative Oncology Group (ECOG) =< 1
- If cirrhosis, Child-Pugh classification A or B
- Total bilirubin =< 3.0 mg/dL
- Creatinine =< 1.5 x upper limit of normal for the laboratory
- International normalized ratio (INR) =< 1.7 (if not due to anticoagulants)
- Absolute neutrophil count (ANC) >= 1,500/mm^3
- Platelets >= 80,000/mm^3
- Hemoglobin (Hgb) >= 8.5 g/dL (transfusion or erythropoietin-like substances not permitted prior to baseline evaluation)
- Any prior therapies such as surgery, chemoembolization, radiofrequency ablation, and alcohol injection are allowed as long as toxicity from such prior therapy is =< grade 1
- Prior sorafenib is allowed as long as toxicity from ongoing is ≤ grade 2 and prior intolerance of 400 mg sorafenib PO daily is felt amenable, by the principal investigator, to supportive care measures or dose modifications.
- Measurable or evaluable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria version (v) 1.1 mRECIST or elevated AFP
- Ability to understand and willingness to sign a written informed consent; a signed informed consent must be obtained prior to any study specific procedures
- Women of childbearing potential must have a negative pregnancy test performed within 2 weeks prior to the start of treatment
- Women of childbearing potential and men must agree to use a medically accepted form of birth control for the duration of study participation and for 4 months following completion of study treatment
Exclusion Criteria:
- Candidate for curative therapy including surgical resection or orthotopic liver transplantation
- Known central nervous system metastasis
- Any investigational agent within 4 weeks of first dose of study treatment
- Known intolerance of vorinostat
- Unable to swallow medication
- Unable to swallow medication; suspected malabsorption
- Active alcohol abuse
Contraindication to antiangiogenic agents, including:
- Pulmonary hemorrhage/bleeding event >= grade 2 within 4 weeks of first dose of study drug
- Any other hemorrhage/bleeding event >= grade 3 within 4 weeks of first dose of study treatment
- Serious non-healing wound, ulcer, or bone fracture
- Thrombolic or embolic events such as a cerebrovascular accident including transient ischemic attacks within the past 6 months; hepatic portal vein thrombus is not considered an exclusion criterion
- Major cardiac dysfunction, such as uncontrolled angina, congestive heart failure with New York Heart Association (NYHA) class III or higher, known left ventricular ejection fraction less than 40%
- Systolic blood pressure > 160 mmHg or diastolic pressure > 90 mmHg despite optimal medical management
- Significant lung disease (oxygen [O2] saturation less than 88% in room air)
- Serious uncontrolled infection; known human immunodeficiency virus (HIV)-seropositivity requiring retroviral therapy, or diagnosis of acquired immune deficiency syndrome (AIDS); diagnosis of chronic hepatitis B or C allowed
- Medical, psychological, or social conditions that, in the opinion of the investigator, may increase the patient's risk or interfere with the patient's participation in the study or hinder evaluation of the study results
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm A
Sorafenib + Vorinostat.
Patients receive sorafenib tosylate PO BID continuously and vorinostat PO QD, for 5 days each week.
Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
Cohort A has only one dose level: sorafenib 400 mg orally twice a day with vorinostat 300 mg orally.
Cohort A was modified to include 2 dose levels: Dose level A1 (sorafenib 400 mg orally twice a day and vorinostat 200 mg orally once a day) and dose level A-1 (sorafenib 400 mg orally twice a day with vorinostat 100 mg orally once a day).
The starting dose upon reopening after approval of this version will be dose level A-1a.
Dose level A1 will only be used if dose level A-1a is not tolerable.
|
Given orally
Other Names:
Given orally
Other Names:
|
Experimental: Arm B CLOSED
Reduced Dose 200mg Sorafenib + Vorinostat.
Patients receive sorafenib tosylate PO BID continuously and vorinostat PO QD, for 5 days each week.
Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
Cohort B has 2 dose levels starting at the second dose level (sorafenib 200 mg orally twice a day with vorinostat 400 mg orally).
Cohort B has been closed.
Cohort B was intended to evaluate the possibility of dose intensification of vorinostat when patients were unable to tolerate standard dose sorafenib, and required dose-reduced sorafenib.
The patients accrued to date in Cohort B were unable to tolerate therapy, and it has been determined that dose intensification of vorinostat is not possible, despite reducing the dose of sorafenib.
|
Given orally
Other Names:
Given orally
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Determine the appropriate Doses for the combination of sorafenib tosylate and vorinostat appropriate for phase II study in hepatocellular carcinoma (HCC).
Time Frame: 4 weeks
|
Identify the maximum tolerated dose of the combination regimen of vorinostat and sorafenib to study further for efficacy of treatment for hepatocellular carcinoma
|
4 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse events will be characterized in terms of nature, severity, attribution, onset and resolution according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0.
Time Frame: Up to 30 days post-treatment
|
Safety, tolerance, and toxicity of the combination of sorafenib tosylate and vorinostat in patients with HCC.
Observe toxicities experienced by patients treated in cohorts of escalating doses of the drug combination.
|
Up to 30 days post-treatment
|
Anti-tumor effects of the combination of sorafenib tosylate and vorinostat
Time Frame: Up to 6 years
|
Tumor masses will be evaluated for response according to the RECIST Criteria.
Summarized using descriptive statistics for each cohort, along with their corresponding 95% confidence intervals.
|
Up to 6 years
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Andrew S. Poklepovic, MD, Massey Cancer Center
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- MCC-12122
- NCI-2010-00185
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Liver Cancer
-
Slawa CwajnaNova Scotia Health AuthorityWithdrawnPrimary Liver Cancer | Metastatic Liver CancerCanada
-
Duke UniversityCompletedPrimary Liver Cancer | Metastatic Liver Cancer From Any Cancer SiteUnited States
-
University of HawaiiGlaxoSmithKlineRecruitingAdvanced Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Adult Primary Liver CancerUnited States
-
Célia TurcoCompletedPrimary Liver Cancer | Liver Metastases | Secondary Liver CancerFrance
-
University of CincinnatiActive, not recruitingLiver Metastases | Advanced Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Recurrent Adult Primary Liver CancerUnited States
-
Lisa H. Butterfield, Ph.D.National Cancer Institute (NCI)TerminatedHepatocellular Carcinoma | Liver Cancer | Cancer of Liver | Hepatoma | Hepatocellular Cancer | Hepatic Cancer | Liver Cell Carcinoma | Cancer, Hepatocellular | Liver Cancer, Adult | Liver Cell Carcinoma, Adult | Cancer of the Liver | Neoplasms, Liver | Hepatic Neoplasms | Neoplasms, HepaticUnited States
-
Radboud University Medical CenterTerumo Medical CorporationCompletedPrimary Liver Cancer | Liver Cancer | Liver Metastasis Colon CancerNetherlands
-
Cardiovascular and Interventional Radiological...RecruitingPrimary Liver Cancer | Secondary Liver CancerGermany
-
Shanghai Huihe Medical Technology Co., LtdEnrolling by invitation
-
Burzynski Research InstituteTerminatedPrimary Liver CancerUnited States
Clinical Trials on sorafenib tosylate
-
National Cancer Institute (NCI)CompletedMultiple Endocrine Neoplasia Type 2A | Multiple Endocrine Neoplasia Type 2B | Recurrent Thyroid Gland Medullary Carcinoma | Hereditary Thyroid Gland Medullary Carcinoma | Locally Advanced Thyroid Gland Medullary Carcinoma | Sporadic Thyroid Gland Medullary Carcinoma | Stage III Thyroid Gland Medullary... and other conditionsUnited States
-
National Cancer Institute (NCI)Active, not recruitingGastrointestinal Stromal TumorUnited States
-
National Cancer Institute (NCI)CompletedPreviously Treated Myelodysplastic Syndrome | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Recurrent Adult Acute Lymphoblastic Leukemia | Secondary Myelodysplastic Syndrome | de Novo Myelodysplastic Syndrome | Adult Acute Monoblastic Leukemia | Adult Acute Monocytic... and other conditionsUnited States
-
National Cancer Institute (NCI)Gynecologic Oncology GroupCompletedRecurrent Ovarian Carcinoma | Primary Peritoneal CarcinomaUnited States
-
Roswell Park Cancer InstituteNational Comprehensive Cancer NetworkCompletedAdvanced Adult Hepatocellular Carcinoma | Localized Non-Resectable Adult Hepatocellular Carcinoma | Stage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular Carcinoma | Stage III... and other conditionsUnited States
-
Ohio State University Comprehensive Cancer CenterBayerTerminated
-
Kyowa Hakko Kirin Pharma, Inc.CompletedPeripheral T-Cell LymphomaUnited States
-
National Cancer Institute (NCI)CompletedJuvenile Myelomonocytic Leukemia | Recurrent Disease | Recurrent Childhood Acute Lymphoblastic Leukemia | Recurrent Childhood Acute Myeloid Leukemia | Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Childhood Solid Neoplasm | Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Philadelphia... and other conditionsUnited States, Canada
-
National Cancer Institute (NCI)CompletedAdvanced Malignant NeoplasmUnited States
-
National Cancer Institute (NCI)CompletedHilar Cholangiocarcinoma | Recurrent Gallbladder Carcinoma | Unresectable Extrahepatic Bile Duct Carcinoma | Unresectable Gallbladder Carcinoma | Gallbladder Adenocarcinoma | Recurrent Extrahepatic Bile Duct Carcinoma | Extrahepatic Bile Duct Adenocarcinoma | Gallbladder Adenocarcinoma With Squamous... and other conditionsUnited States